B. Lisboa

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Maxime P. Look, Wim L.J. van Putten, Michael J. Duffy et al. · JNCI Journal of the National Cancer Institute · 2002 · 604 citations · Full text

Medicine, Biostatistics, Oncology +15

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study

W. Jonat, M. Kaufmann, Willi Sauerbrei et al. · Journal of Clinical Oncology · 2002 · 338 citations

Medicine, Oncology, Pharmacotherapy +13

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

Nadia Harbeck, Manfred Schmitt, Christoph Meisner et al. · European Journal of Cancer · 2013 · 165 citations

Medicine, Oncology, Breast Oncology +9

Differential Expression of CD66a (BGP), a Cell Adhesion Molecule of the Carcinoembryonic Antigen Family, in Benign, Premalignant, and Malignant Lesions of the Human Mammary Gland

Lutz Riethdorf, B. Lisboa, U Henkel et al. · Journal of Histochemistry & Cytochemistry · 1997 · 101 citations · Full text

Medicine, Oncology, Pathology +17

Expression pattern of the AP-1 family in breast cancer: Association of fosB expression with a well-differentiated, receptor-positive tumor phenotype

Ana‐Maria Bamberger, Carola Methner, B. Lisboa et al. · International Journal of Cancer · 1999 · 97 citations · Full text

Medicine, Molecular Biology, Oncology +17